Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive ...

Cobenfy contains xanomeline, which helps schizophrenia symptoms, and trospium, which works to reduce the side effects. Psychosis occurs when you lose touch with reality and experience ...

One of the most promising developments in this area is the exploration of mAChR agonists, such as xanomeline, which has shown efficacy in reducing psychotic symptoms and improving cognitive ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Xanomeline activates certain so-called muscarinic ... But as people progress through their disease, they experience symptoms such as psychosis and agitation, Bristol Myers Squibb's Elkins said. " ...

KarXT is an oral, investigational muscarinic agonist comprised of the muscarinic agonist xanomeline and muscarinic ... including schizophrenia and psychosis in Alzheimer’s disease.